Barclays analyst Balaji Prasad lowered the firm’s price target on Coherus Biosciences to $7 from $8 and keeps an Overweight rating on the shares. The analyst says specialty pharma heads into Q3 earnings “in one of the weakest sentiments we have seen.” The firm believes growth concerns have escalated for Coherus.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus announces toripalimab data at AACR-NCI-EORTC International Conference
- Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Biotech Alert: Searches spiking for these stocks today
- Coherus Biosciences price target lowered to $6 from $7 at BofA
- ‘Load Up,’ Says Citigroup, About These 2 ‘Strong Buy’ Stocks